Anti-thrombin III and Heparin Clotting Times in Thrombosis and Atherosclerosis

J. R O’Brien

doi:10.1055/s-0038-1647678

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1974; 32(01): 116-123
DOI: 10.1055/s-0038-1647678

Original Article

Schattauer GmbH

Anti-thrombin III and Heparin Clotting Times in Thrombosis and Atherosclerosis

J. R O’Brien

¹Portsmouth and Isle of Wight Area Pathology Service Central Laboratory, Portsmouth, P03 6 AG, England

› Author Affiliations

Abstract

Summary

A survey of the literature shows that when whole blood clots thrombin is formed and there is a decrease in anti-thrombin III (Anti-Th. Ill) and an increase in heparin neutralizing activity (HNA) which is probably identical to platelet factor 4 derived from platelets. Many studies of atherosclerosis and of arterial and venous thrombosis using various tests thought to measure Anti-Th. Ill and HNA report a decrease in Anti-Th. Ill or an increase in HNA or both. We have measured both in patients with atherosclerosis and survivors of myocardial infarction. The HNA was increased and the serum anti-thrombic activity was decreased relative to controls and there was an inverse correlation between the two measurements. All this evidence suggests that some kind of mild chronic intravascular coagulation may occur in atherosclerosis. These changes could be related to the cause or the result of atherosclerosis.

Full Text

References

References
1 Biggs R, Denson K. W. E, Akman N, Borrett R, Hadden M. 1970; Antithrombin III, antifactor Xa and heparin. British Journal of Haematology 19: 283.
2 Biggs R, Denson K. W. E, Akman N, Borrett R, Hadden M. 1970; Antithrombin III, antifactor Xa and heparin. British Journal of Haematology 19: 283.
3 Cotton R. C, Shaikh M. S, Dent R. V. 1968; Heparin resistance and plasma fibrinogen in elderly subjects with and without occlusive vascular disease. Journal of Atherosclerosis Research 08: 959.
4 Cotton R. C, Bloor K, Archibald G. 1972; Inter-relationships between platelet response to adenosine diphosphate, blood coagulation and serum lipids in patients with peripheral occlusive atherosclerosis. Atherosclerosis 16: 337.
5 Duguid J. B. 1946; Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. Journal of Pathology and Bacteriology 58: 207.
6 Egeberg O. 1965; Inherited antithrombin deficiency causing thrombophilia. Thrombosis et Diathesis Haemorrhagica IS: 516.
7 Fagerhol M. K, Abildgaard U. 1970; Immunological studies on human antithrombin III. Scandinavian Journal of Haematology 07: 10.
8 Farbiszewski R, Niewiarowski S, Worowski K, Lipinski B. 1968; Release of platelet factor 4 in vivo during intravascular coagulation and in thrombotic states. Thrombosis et Diathesis Haemorrhagica 19: 578.
9 Fletcher A. P, Alkjaersig N, O’Brien J. R, Tulevski V. G. 1970; “Blood hypercoagulability” and thrombosis. Transactions of the American Association of Physicians 83: 159.
10 Fitster V, Bowie E. J. W, Kazmier F. J, Owen Jr C. A. 1974; Plasma platelet factor 4-like activity reflecting the rate of platelet consumption in chronically induced intravascular coagulation in dogs. Thrombosis Research 04: 247.
11 Gormsen J. 1959; A technique for the heparin tolerance test. British Journal of Haematology 05: 257.
12 Gormsen J, Haxholdt F. I. B. 1960; The heparin tolerance test and thromboembolic incidence in surgery. Acta Chirurgica Scandinavica 120: 121.
13 Harker L. A, Slighter S. J. 1972; Platelet and fibrinogen consumption in man. New England Journal of Medicine 287: 999.
14 Inman W. H. W, Yessey M. P, Westerholm B, Engelund A. 1970; Thromboembolic disease and the steroidal content of oral contraceptives. British Medical Journal 02: 203.
15 Innés D, Sevitt S. 1964; Coagulation and fibrinolysis in injured patients. Journal of Clinical Pathology 17: 1.
16 Kakkar Y. Y, Corrigan T, Spindler J, Fossard D. P, Flute P. T, Crellin R. Q, Wessler S, Yin E. T. 1972; Efficacy of low doses of heparin in the prevention of deep vein thrombosis after major surgery. Lancet 02: 101.
17 Von Katjlla E, von Katjlla K. N. 1967; Antithrombin III and diseases. American Journal of Clinical Pathology 48: 69.
18 von Katjlla E, Droegmueller W, Aoki N, von Katjlla K. N. 1971; Antithrombin III depression and thrombin generation acceleration in women taking oral contraceptives. American Journal of Obstetrics and Gynaecology 109: 868.
19 McDonald L, Edgill M. 1961; Action of heparin on ischaemic heart disease. Lancet 01: 844.
20 Marciniak E, Farley C. H, de Simone P. A. 1974; Familial thrombosis due to antithrombin III deficiency. Blood 43: 219.
21 Van der Meer J, SïOEPMAN-van Dalen E. A, Jansen J. M. S. 1973; Antithrombin III deficiency in a Dutch family. Journal of Clinical Pathology 26: 532.
22 Moore S, Pepper D. S. 1973; Platelet specific release products to monitor function in vivo. Scottish Medical Journal 18: 216.
23 Nath N, Niewiarowski S, Joist J. H. 1973; Platelet factor 4 - antiheparin protein releasable from platelets, purification and properties. Journal of Laboratory and Clinical Medicine 82: 754.
24 O’Brien J. R. 1960; The effect of heparin on the early stages of blood coagulation. Journal of Clinical Pathology 13: 93.
25 O’Brien J. R, Tulevski Y. G, Etherington M, Madgwick T, Alkjaersig N, Fletcher A. (1974a): Platelet function studies before and after operation and the effect of postoperative thrombosis. Journal of Laboratory and Clinical Medicine 83: 342.
26 O’Brien J. R, Etherington M, Jamieson S, Klaber M. R, Lincoln S. Y. (1974b): Platelet function long after arterial and venous thrombosis. Thrombosis et Diathesis Haemorrhagica 31: 279.
27 O’Brien J. R, Etherington M, Jamieson S, Lawford P. (1974c): Blood changes in atherosclerosis and long after myocardial infarction and venous thrombosis. In preparation..
28 Sear C. H. J, Poller L. 1973; Antiheparin activity of human serum and platelet factor 4. Thrombosis et Diathesis Haemorrhagica 30: 93.
29 Steele P. P, Weily H. S, Davies H, Genton E. 1974; Platelet survival in patients with rheumatic heart disease. New England Journal of Medicine 290: 537.
30 Yin E. T, Wessler S, Stoll P. J. 1971; Identity of plasma-activated Factor X inhibitor with antithrombin III and heparin cofactor. The Journal of Biological Chemistry 246: 3712.